Detailed information |
---|
CancerLivER ID | 2539 |
Biomarker | NRCAM, CD24, CTHRC1, ROBO1, CENPM, FOXQ1, CDCA7L, MYBL2, PAFAH1B3, STK39, SPINK1, AKR1B10, SLC6A8, SOX4, |
Biomarker Name/Symbol (given in Publication) | NRCAM, CD24, CTHRC1, ROBO1, CENPM, FOXQ1, CDCA7-L, MYBL2, PAFAH1B3, STK39, SPINK1, AKR1B10, SLC6A8 and SOX4 |
Biomolecule | RNAs |
Subject | Human |
Degree of Validity | Potential pathological staging marker of HCC and upregulated in T3 than T1 and adjacent non-tumor (with 6 fold change); but not validated on independent dataset |
Experimental Condition | Intrahepatic metastasis v/s primary HCC and normal |
Cancer type | Hepatocellular carcinoma |
Regulation | Upregulated in T3 than T1 and adjacent non-tumor (with 6 fold change) |
Level of significance | p < 0.05 |
Source | Tissue |
PMID | 18504433 |
Type of Biomarker | Prognostic |
Pathway | Adhesion molecules and Transcription factor |
Cohort | Training dataset: 4 primary HCC (T1), 6 intrahepatic metastatic HCC (T3) and 2 normal liver samples (HNL); validation dataset : T3 tumors (n=24) /higher than adjacent normal tissues (n=61, adjacent-average) and T1 tumors (n=15). |
Sensitivity | NA |
Specificity | NA |
Accuracy | NA |
AUC | NA |
Disease | Intrahepatic metastasis v/s primary HCC and normal |
Year of Publication | 2008 |
Clinical trial | NO |
Clinical trial (NCT Number) | NA |